Trial Profile
A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Biodel
- 24 Jan 2013 Results have been reported in a Biodel media release.
- 24 Jan 2013 Status changed from recruiting to completed based on information reported in a Biodel media release.
- 20 Dec 2012 New trial record